News

Filter

Current filters:

Biogen IdecLicensing

1 to 9 of 28 results

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30-05-2014

US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII

21-04-2014

US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

10-01-2014

US biotech firm Biogen Idec and Sangamo Biosciences have signed an exclusive worldwide collaboration…

Biogen IdecBiotechnologyHematologyLicensingResearchSangamo BioSciences

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

10-12-2013

US drug developer Proteostasis Therapeutics has entered into a worldwide collaboration with biotech major…

Biogen IdecBiotechnologyLicensingNeurologicalProteostasis TherapeuticsResearch

1 to 9 of 28 results

COMPANY SPOTLIGHT

Menarini

Back to top